UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Medtronic plc (NYSE:MDT - Free Report) by 436.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,343,385 shares of the medical technology company's stock after buying an additional 5,975,110 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.57% of Medtronic worth $661,125,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Noesis Capital Mangement Corp lifted its holdings in Medtronic by 2.5% in the third quarter. Noesis Capital Mangement Corp now owns 101,266 shares of the medical technology company's stock worth $9,117,000 after buying an additional 2,482 shares during the period. Public Sector Pension Investment Board boosted its position in shares of Medtronic by 244.8% during the third quarter. Public Sector Pension Investment Board now owns 175,914 shares of the medical technology company's stock valued at $15,838,000 after purchasing an additional 124,900 shares in the last quarter. Fiduciary Trust Co boosted its position in shares of Medtronic by 0.4% during the third quarter. Fiduciary Trust Co now owns 35,375 shares of the medical technology company's stock valued at $3,185,000 after purchasing an additional 142 shares in the last quarter. CreativeOne Wealth LLC raised its holdings in Medtronic by 279.5% in the third quarter. CreativeOne Wealth LLC now owns 20,672 shares of the medical technology company's stock worth $1,861,000 after purchasing an additional 15,225 shares in the last quarter. Finally, Glenmede Trust Co. NA lifted its position in Medtronic by 31.0% during the third quarter. Glenmede Trust Co. NA now owns 380,554 shares of the medical technology company's stock valued at $34,261,000 after buying an additional 90,111 shares during the period. Institutional investors own 82.06% of the company's stock.
Medtronic Stock Performance
Shares of MDT traded up $0.59 during trading hours on Thursday, hitting $86.27. The stock had a trading volume of 5,106,486 shares, compared to its average volume of 6,284,553. Medtronic plc has a 12 month low of $75.96 and a 12 month high of $92.68. The stock has a fifty day moving average price of $88.75 and a 200 day moving average price of $84.97. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.84 and a quick ratio of 1.39. The firm has a market capitalization of $110.64 billion, a PE ratio of 26.38, a PEG ratio of 2.43 and a beta of 0.84.
Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings results on Tuesday, November 19th. The medical technology company reported $1.26 EPS for the quarter, beating the consensus estimate of $1.25 by $0.01. The firm had revenue of $8.40 billion during the quarter, compared to analyst estimates of $8.27 billion. Medtronic had a net margin of 13.00% and a return on equity of 13.79%. The business's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.25 EPS. Analysts anticipate that Medtronic plc will post 5.46 EPS for the current year.
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on MDT shares. Robert W. Baird decreased their price target on shares of Medtronic from $96.00 to $93.00 and set a "neutral" rating for the company in a research note on Wednesday, November 20th. Stifel Nicolaus boosted their price target on Medtronic from $85.00 to $87.00 and gave the stock a "hold" rating in a research report on Wednesday, August 21st. Oppenheimer raised their price objective on Medtronic from $92.00 to $94.00 and gave the company a "market perform" rating in a research report on Wednesday, August 21st. Daiwa America raised Medtronic to a "strong-buy" rating in a report on Friday, August 23rd. Finally, Wells Fargo & Company reduced their price target on Medtronic from $106.00 to $98.00 and set an "overweight" rating for the company in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Medtronic presently has an average rating of "Hold" and a consensus target price of $95.27.
Read Our Latest Analysis on MDT
About Medtronic
(
Free Report)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Featured Articles
Before you consider Medtronic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.
While Medtronic currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.